Takeda Pharmaceutical Company Limited Stock price

Equities

4502

JP3463000004

Pharmaceuticals

Delayed Japan Exchange 02:00:00 2023-09-27 am EDT Intraday chart for Takeda Pharmaceutical Company Limited 5-day change 1st Jan Change
4810.00 JPY +0.12% -0.21% +17.00%
Sales 2024 * 3,941 B 26,437 M Sales 2025 * 3,886 B 26,074 M Capitalization 7468 B 50 104 M
Net income 2024 * 209 B 1,405 M Net income 2025 * 259 B 1,737 M EV / Sales 2024 *
2,83x
Net Debt 2024 * 3,699 B 24,817 M Net Debt 2025 * 3,406 B 22,853 M EV / Sales 2025 *
2,80x
P/E ratio 2024 *
36,5x
P/E ratio 2025 *
29,7x
Employees -
Yield 2024 *
3,91%
Yield 2025 *
3,97%
Free-Float97.02%
More Fundamentals * Assessed data
Dynamic Chart
Takeda Pharmaceutical's Plasma Therapy Receives Approval in Japan MT
Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema in Patients Aged 2 Years and Older CI
Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema in Patients Aged 2 years and Older CI
Jefferies Adjusts Takeda Pharmaceutical's Price Target to 5,300 Yen From 5,100 Yen, Keeps at Buy MT
Takeda Pharmaceutical Says US FDA Accepted Resubmission of Application for Drug Candidate to Treat Eosinophilic Esophagitis MT
Takeda Announces FDA Acceptance of NDA Resubmission of Tak-721 (Budesonide Oral Suspension) for the Short-Term Treatment of Eosinophilic Esophagitis CI
Takeda Pharmaceutical Says US FDA Accepted Biologics License Application for Entyvio to Treat Crohn's Disease MT
Takeda Pharmaceutical Company Limited Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn?s Disease CI
Takeda's Phase 2b Trial for Oral Treatment in Psoriatic Arthritis Shows Positive Results MT
Transcript : Takeda Pharmaceutical Company Limited Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-11-2023 03:55 PM CI
Brazil's inflation expected to have picked up slightly in August RE
Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a highly selective oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis CI
Amneal Pharmaceuticals Gets US FDA's Abbreviated New Drug Application Approval for Lisdexamfetamine Dimesylate MT
Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse RE
ImmunoGen Signs Exclusive Collaboration with Takeda Pharmaceutical to Develop, Commercialize Elahere in Japan MT
More news
1 day+0.12%
1 week-0.21%
Current month+6.70%
1 month+7.56%
3 months+7.20%
6 months+11.99%
Current year+17.00%
More quotes
1 week
4 701.00
Extreme 4701
4 825.00
1 month
4 453.00
Extreme 4453
4 873.00
Current year
4 004.00
Extreme 4004
4 873.00
1 year
3 663.00
Extreme 3663
4 873.00
3 years
2 993.00
Extreme 2993
4 873.00
5 years
2 894.50
Extreme 2894.5
4 943.00
10 years
2 894.50
Extreme 2894.5
6 693.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 2015
Director of Finance/CFO 52 2018
Chief Tech/Sci/R&D Officer 58 2015
Members of the board TitleAgeSince
Director/Board Member 57 2014
Director/Board Member 64 2016
Director/Board Member 60 2022
More insiders
Date Price Change Volume
23-09-27 4810.00 +0.12% 6 264 100
23-09-26 4804.00 +0.76% 5,331,700
23-09-25 4768.00 +1.21% 3,290,300
23-09-22 4711.00 -0.86% 4,176,200
23-09-21 4752.00 -1.41% 4,864,000

Delayed Quote Japan Exchange, September 27, 2023 at 02:00 am EDT

More quotes
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas: - sale of drugs and consumer care products; - services. Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
4804.00JPY
Average target price
4782.11JPY
Spread / Average Target
-0.46%
Consensus
  1. Markets
  2. Equities
  3. Stock Takeda Pharmaceutical Company Limited - Japan Exchange
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration
fermer